|

B group Purinostat Mesylate 11.2mg/m2 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Chengdu Zenitar Biomedical Technology Co., Ltd1

Indications

  • Advanced Solid Tumor1
  • Cancer1

Other1 trial

A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.